The cost-effectiveness of interferon beta treatment in patients with a clinically isolated syndrome in Colombia
Abstract
Introduction: Approximately 85% of patients with multiple sclerosis have an initial demyelinating event. Treatment with interferon beta delays the progression of multiple sclerosis for nearly two years in patients with a clinically isolated syndrome. In Colombia, interferon is very expensive when compared to other countries.
Objective: Purpose: We sought to determine the cost-effectiveness of a two-year interferon beta treatment within Colombia in patients with a clinically isolated syndrome.
Materiales y methods: Based on patient and society perspectives, a cost-effectiveness analysis was conducted using a decision tree. A variety of probabilities were defined after a systematic review of the available literature. The disease costs were calculated by reviewing medical charts at the Hospital San Ignacio University and surveys completed by multiple sclerosis patients. To control for uncertainty in these data, analysis of approximately one-thousand patients was performed using Monte Carlo methods.
Results: The two-year treatment cost per patient exceeds Col$ 95,000,000 (US$ 50,000). Approximately 80 % of this cost corresponds to medications (US$ 40,500). The price of relapse and indirect costs totals Col$ 41,632,149 (US$ 21,744) and Col$ 11,656,389 (US$ 6,088), respectively. Treatment represents an increase of 0.06 quality-adjusted life years (QALY). The incremental cost-effectiveness ratio exceeds the threshold, regardless of the use of Monte Carlo methods for analysis.
Conclusion: Administering interferon beta over the course of two years to high-risk patients with a clinically isolated syndrome is not cost-effective within Colombia.
Downloads
Some similar items:
- Álvaro Sanabria, Javier Romero, Miguel Angarita, Juan Carlos Varón, Cost-effectiveness of computed tomography and ultrasound in the diagnosis of appendicitis , Biomedica: Vol. 28 No. 1 (2008)
- Óscar Gamboa, Sandra Díaz, Liliana Chicaíza, Mario García, Cost-benefit analysis of anastrazol and tamoxifen in adjuvant treatment of hormone receptor-positive, post-menopausal breast cancer , Biomedica: Vol. 30 No. 1 (2010)
- Sandra Lorena Girón, Julio César Mateus, Carlos Enrique Castellar, Cost-effectiveness analysis of two strategies for malaria control in the urban area of , Biomedica: Vol. 26 No. 3 (2006)
- Liliana Alejandra Chicaíza-Becerra, Mario García-Molina, Óscar Gamboa, Cost-effectiveness of iso- versus low-osmolality contrast media in outpatients with high risk of contrast medium-induced nephropathy , Biomedica: Vol. 32 No. 2 (2012)
- Roosevelt Fajardo, José Ignacio Valenzuela, Sandra Catalina Olaya, Gustavo Quintero, Gabriel Carrasquilla, Carlos Eduardo Pinzón, Catalina López, Juan Camilo Ramírez, Cost-effectiveness of laparoscopic versus open cholecystectomy , Biomedica: Vol. 31 No. 4 (2011)
- Juan Carlos Villa-Camacho, Juan Camilo Vargas-Zambrano, John Mario González, Flow cytometry model for the detection of neutralizing antibodies against of IFN-β , Biomedica: Vol. 32 No. 4 (2012)
- Aurelio Mejía, Walter Salas, Cost effectiveness of human papilloma virus testing in cervical cancer screening: A literature review , Biomedica: Vol. 28 No. 1 (2008)
- Álvaro Sanabria, Adonis Ramírez, Economic analysis of routine neuromonitoring of recurrent laryngeal nerve in total thyroidectomy , Biomedica: Vol. 35 No. 3 (2015)
- Jefferson Antonio Buendía, Juana Patricia Sánchez-Villamil, Gabriela Urman, Cost-effectiveness of diagnostic strategies of severe bacterial infection in infants with fever without a source , Biomedica: Vol. 36 No. 3 (2016)
- Julio César Martinez, Sandra Patricia Misnaza, Rare diseases mortality in Colombia, 2008-2013 , Biomedica: Vol. 38 No. 2 (2018)
Article metrics | |
---|---|
Abstract views | |
Galley vies | |
PDF Views | |
HTML views | |
Other views |